Aquinnah Pharmaceuticals is using newly discovered brain pathology to design innovative therapies to slow the progression of ALS and other neurodegenerative diseases. Aquinnah builds on the groundbreaking work of co-founder Benjamin Wolozin, M.D., Ph.D., who has led the discovery of disease-linked protein aggregation in neurologic diseases.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/21/15 | $5,000,000 | Strategic |
Takeda Ventures | undisclosed |
